Work

Improving response to olaparib in uterine serous cancer through treatment with AVB500, a receptor tyrosine kinase AXL inhibitor

Year: 2020

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2020.05.373

Authors: M.D. Toboni, M.M. Mullen, J.I. Tankou, H. Noia, A. Oplt, D. Wilke, P. Cannon, L.M. Kuroki, A.R. Hagemann, C.K. McCourt, P.H. Thaker, D.G. Mutch, M.A. Powell, K.C. Fuh

Institution: Washington University in St. Louis

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4250099765

FWCI:

Cites:

Cited by:

Related to: 10